NASDAQ:GMDA

Gamida Cell - GMDA Stock Forecast, Price & News

$1.27

-0.02 (-1.16%)

(As of 12/9/2022 11:24 AM ET)

Add

Compare

Today's Range: $1.24
▼
$1.28
50-Day Range: $1.29
▼
$2.10
52-Week Range: $1.26
▼
$4.72

Volume: 6,039 shs
Average Volume: 595,447 shs
Market Capitalization: $75.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.80

Gamida Cell MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 907.9% Upside
$12.80 Price Target
Short Interest: Bearish
6.00% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$39,999 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.18) to ($0.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

784th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

128th out of 171 stocks

3.5

Analyst's Opinion

Consensus Rating
Gamida Cell has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.80, Gamida Cell has a forecasted upside of 907.9% from its current price of $1.27.
Amount of Analyst Coverage
Gamida Cell has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.00% of the outstanding shares of Gamida Cell have been sold short.
Short Interest Ratio / Days to Cover
Gamida Cell has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in Gamida Cell has recently increased by 4.11%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Gamida Cell does not currently pay a dividend.
Dividend Growth
Gamida Cell does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GMDA.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Gamida Cell this week, compared to 1 article on an average week.
Search Interest
14 people have searched for GMDA on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
MarketBeat Follows
7 people have added Gamida Cell to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gamida Cell insiders have bought more of their company's stock than they have sold. Specifically, they have bought $39,999.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of Gamida Cell is held by insiders.
Percentage Held by Institutions
41.27% of the stock of Gamida Cell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Gamida Cell are expected to grow in the coming year, from ($1.18) to ($0.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gamida Cell is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gamida Cell is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gamida Cell has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gamida Cell (NASDAQ:GMDA) Stock

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Stock News Headlines

December 9, 2022 | americanbankingnews.com

Head to Head Analysis: Gamida Cell (NASDAQ:GMDA) and Mosaic ImmunoEngineering (OTCMKTS:CPMV)

November 21, 2022 | finance.yahoo.com

Gamida Cell Provides Regulatory Update on Omidubicel

December 9, 2022 | Investing Trends (Ad)

"We need batteries. Literally everywhere."

Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."

November 14, 2022 | finance.yahoo.com

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

November 10, 2022 | finance.yahoo.com

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference

November 7, 2022 | finance.yahoo.com

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

November 7, 2022 | finance.yahoo.com

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers

November 3, 2022 | finance.yahoo.com

Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting

December 9, 2022 | PressReach (Ad)

Top Innovation Stock

Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.

October 10, 2022 | finance.yahoo.com

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa

September 29, 2022 | markets.businessinsider.com

Gamida Cell: Omidubicel Follow Up Data Shows 63% Overall Survival At Three Years

September 29, 2022 | finance.yahoo.com

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

September 28, 2022 | marketwatch.com

Gamida Cell Shares Slide Premarket After Public Offering, Financing >GMDA

September 28, 2022 | finance.yahoo.com

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares

September 28, 2022 | finance.yahoo.com

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

September 19, 2022 | marketwatch.com

Gamida Cell Names Abigail L. Jenkins as President, CEO

September 19, 2022 | markets.businessinsider.com

Gamida Cell Appoints Abigail Jenkins To Succeed Julian Adams As President And CEO

September 19, 2022 | finance.yahoo.com

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

September 12, 2022 | finance.yahoo.com

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

August 17, 2022 | msn.com

Earnings

August 15, 2022 | fool.com

Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript

August 15, 2022 | seekingalpha.com

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2022 Results - Earnings Call Transcript

August 15, 2022 | finance.yahoo.com

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

August 10, 2022 | finance.yahoo.com

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

August 9, 2022 | finance.yahoo.com

These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer

August 8, 2022 | finance.yahoo.com

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

August 4, 2022 | finance.yahoo.com

How Many Gamida Cell Ltd. (NASDAQ:GMDA) Shares Do Institutions Own?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Company Calendar

Last Earnings: 11/14/2022
Today: 12/09/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GMDA
CUSIP: N/A
CIK: 1600847
Web: www.gamida-cell.com
Phone: (722) 659-5666
Fax: N/A
Employees: 166
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.80
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +903.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -387.05%
Return on Assets: -70.54%

Debt

Debt-to-Equity Ratio: 5.31
Current Ratio: 2.76
Quick Ratio: 2.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.74 per share
Price / Book: 1.72

Miscellaneous

Outstanding Shares: 59,200,000
Free Float: 57,661,000
Market Cap: $75.48 million
Optionable: Not Optionable
Beta: 1.58

Key Executives

Mr. Shai Lankry CPA (Age 46)
M.B.A., Chief Financial Officer
Comp: $564k

Ms. Michele Ilene Korfin M.B.A. (Age 50)
R.Ph., Chief Operating & Chief Commercial Officer
Comp: $510k

Dr. Ronit Simantov M.D. (Age 57)
Chief Medical & Chief Scientific Officer
Comp: $581k

Dr. Jas Uppal Ph.D. (Age 54)
Chief Regulatory Officer
Comp: $476k

Ms. Abigail L. Jenkins (Age 46)
Pres, CEO & Director

Mr. Joshua F. Patterson (Age 46)
Gen. Counsel & Chief Compliance Officer

Mr. Paul Nee
VP of Marketing

Mr. Naftali Brikashvili CPA
Sr. VP Fin. & Operations

Dr. Tracey Lodie Ph.D. (Age 52)
Scientific Advisor & Consultant

Mr. Vladimir Melnikov
Sr. VP of Global Operations & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GMDA Stock - Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings or view top-rated stocks.
What is Gamida Cell's stock price forecast for 2023?: 5 equities research analysts have issued 12-month price targets for Gamida Cell's stock. Their GMDA share price forecasts range from $7.00 to $22.00. On average, they expect the company's share price to reach $12.80 in the next year. This suggests a possible upside of 907.9% from the stock's current price.
View analysts price targets for GMDA or view top-rated stocks among Wall Street analysts.
How have GMDA shares performed in 2022?: Gamida Cell's stock was trading at $2.54 at the start of the year. Since then, GMDA shares have decreased by 50.0% and is now trading at $1.27.
View the best growth stocks for 2022 here.
When is Gamida Cell's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our GMDA earnings forecast.
How were Gamida Cell's earnings last quarter?: Gamida Cell Ltd. (NASDAQ:GMDA) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.02.
What other stocks do shareholders of Gamida Cell own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN).

When did Gamida Cell IPO?: (GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.
What is Gamida Cell's stock symbol?: Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."
Who are Gamida Cell's major shareholders?: Gamida Cell's stock is owned by many different institutional and retail investors. Top institutional shareholders include Meitav Dash Investments Ltd. (6.17%), Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD (3.74%), Federated Hermes Inc. (2.60%), Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD (1.35%), BlackRock Inc. (0.78%) and Marshall Wace LLP (0.62%). Insiders that own company stock include Abigail L Jenkins and Stephen T Wills.
View institutional ownership trends.
How do I buy shares of Gamida Cell?: Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Gamida Cell's stock price today?: One share of GMDA stock can currently be purchased for approximately $1.27.
How much money does Gamida Cell make?: Gamida Cell (NASDAQ:GMDA) has a market capitalization of $75.18 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.
How many employees does Gamida Cell have?: The company employs 166 workers across the globe.
How can I contact Gamida Cell?: Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (722) 659-5666 or via email at irpr@gamida-cell.com.

This page (NASDAQ:GMDA) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial